Pritelivir mesylate hydrate AIC316 mesylate hydrate; BAY 57-1293 mesylate hydrate|cas:1428321-10-1|西域试剂

Pritelivir mesylate hydrate AIC316 mesylate hydrate; BAY 57-1293 mesylate hydrate,99.51%

产品编号：Bellancom-15303B| CAS NO：1428321-10-1| 分子式：C₁₉H₂₄N₄O₇S₃| 分子量：516.61

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-15303B	￥500.00	杭州北京（现货）
Bellancom-15303B	￥700.00	杭州北京（现货）
Bellancom-15303B	￥1500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Pritelivir mesylate hydrate AIC316 mesylate hydrate; BAY 57-1293 mesylate hydrate

产品介绍

Pritelivir mesylate hydrate (BAY 57-1293 mesylate hydrate) 是一种病毒解旋酶-引物酶复合物 (helicase-primase complex) 抑制剂，在体外和单纯疱疹病毒 (HSV) 感染的动物模型中均具有抗病毒活性。Pritelivir mesylate hydrate 对 1 型和 2 型单纯疱疹病毒 (HSV-1 和 HSV-2) 具有活性，对 HSV1-2 的 IC₅₀ 为 0.02 μM。

生物活性

Pritelivir mesylate hydrate (BAY 57-1293 mesylate hydrate), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir mesylate hydrate is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC₅₀ of 0.02 μM against HSV1-2.

体外研究

体内研究

Pritelivir is the first in a class of antiviral agents that inhibit HSV replication by targeting the viral helicase–primase enzyme complex.
Pritelivir (0.03-45 mg/kg) significantly increases survival. Pritelivir (0.3-30 mg/kg) reduces mortality against HSV-1, E-377. Pritelivir has potent and resistance-breaking antiviral efficacy with potential for the treatment of potentially life-threatening HSV type 1 and 2 infections, including herpes simplex encephalitis.
Combination therapies of Pritelivir at 0.1 or 0.3 mg/kg/dose with Acyclovir (10 mg/kg/dose) are protective when compared to the vehicle treated group against HSV-2, strain MS.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c mice
Dosage:	0.03 to 45 mg/kg
Administration:	Administered orally, twice daily at approximately 12 h intervals, for 7 days
Result:	Survival was significantly increased to 80-100% as compared to the vehicle treatment. Even the lowest dose of 0.3 mg/kg was effective in increasing survival to 53%.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c mice
Dosage:	0.03 to 45 mg/kg
Administration:	Administered orally, twice daily at approximately 12 h intervals, for 7 days
Result:	Survival was significantly increased to 80-100% as compared to the vehicle treatment. Even the lowest dose of 0.3 mg/kg was effective in increasing survival to 53%.